What variables were associated with the inducibility of ventricular fibrillation during electrophysiologic stimulation test in patients without apparent organic heart disease?
- PMID: 20350514
- DOI: 10.1016/j.jjcc.2010.01.006
What variables were associated with the inducibility of ventricular fibrillation during electrophysiologic stimulation test in patients without apparent organic heart disease?
Abstract
Objective: The purpose of our study was to determine what variables were associated with ventricular fibrillation (VF) induced during electrophysiological stimulation test in patients without apparent organic heart disease.
Methods: Our study evaluated 77 patients (51+/-15 years) who underwent electrophysiological stimulation test, signal averaging, and Na+ channel-blocker challenge test (pilsicainide test). The subjects were divided into two groups, the Brugada group and non-Brugada group. Further, the patients were divided into three subgroups on the base of symptoms (8, 7 symptomatic; 9, 13 syncope; 28, 12 asymptomatic group; in the Brugada and non-Brugada groups, respectively). Multivariate analyses evaluated the association between baseline clinical factors and the induction of VF.
Results: The inducibility of VF was significantly (p<0.0001) higher in the Brugada group (n=33, 73%) than the non-Brugada group (n=4, 13%). The multivariate analysis demonstrated that symptoms (odds ratio (OR) 31.6; 95% confidence interval (CI): 2.3-430.6; p<0.01), type 1 electrocardiogram after pilsicainide test (OR 21.3; CI: 1.7-272.2; p<0.02), and syncope (OR 13.5; CI: 1.2-158.8; p<0.05) were strongly associated with the inducibility of VF, but not with family history, type 1 electrocardiogram in control, positive in late potential, maxDeltaST elevation (>==200microV) after pilsicainide test.
Conclusions: The symptoms, syncope, and type 1 electrocardiogram after pilsicainide test were independently associated with the electrophysiological substrate of VF in patients without apparent heart disease.
Copyright 2010. Published by Elsevier Ltd.
Similar articles
-
The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome.J Cardiovasc Electrophysiol. 2006 Jun;17(6):602-7. doi: 10.1111/j.1540-8167.2006.00424.x. J Cardiovasc Electrophysiol. 2006. PMID: 16836706
-
Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome.J Cardiovasc Electrophysiol. 2008 Jan;19(1):56-61. doi: 10.1111/j.1540-8167.2007.00967.x. Epub 2007 Oct 4. J Cardiovasc Electrophysiol. 2008. PMID: 17916151 Clinical Trial.
-
Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome.Pacing Clin Electrophysiol. 2007 May;30(5):662-71. doi: 10.1111/j.1540-8159.2007.00728.x. Pacing Clin Electrophysiol. 2007. PMID: 17461877
-
Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data.Eur Heart J. 2007 Sep;28(17):2126-33. doi: 10.1093/eurheartj/ehm116. Epub 2007 May 5. Eur Heart J. 2007. PMID: 17483540 Review.
-
Efficacy of quinidine in high-risk patients with Brugada syndrome.Circulation. 2004 Sep 28;110(13):1731-7. doi: 10.1161/01.CIR.0000143159.30585.90. Epub 2004 Sep 20. Circulation. 2004. PMID: 15381640 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources